Download full-text PDF

Source
http://dx.doi.org/10.1103/physrevd.31.1136DOI Listing

Publication Analysis

Top Keywords

crossing versus
4
versus noncrossing
4
noncrossing quark-line
4
quark-line diagrams
4
diagrams p-barp-->two
4
p-barp-->two mesons
4
crossing
1
noncrossing
1
quark-line
1
diagrams
1

Similar Publications

Background & Aim: Metabolic and cardiovascular health outcomes are strongly influenced by diet. Dietary habits established in early childhood may persist into adulthood. This study aimed to examine the association between dietary patterns at both 2 and 8 years of age, explaining the maximum variability of high- and low-quality fats, sugars, and fibre, and cardiometabolic markers at age 8 years.

View Article and Find Full Text PDF

Introduction: The relationship between 24-h movement behaviours (i.e. sleep, sedentary behaviour and physical activity) and adiposity in preschoolers remains unclear.

View Article and Find Full Text PDF

National Survey of Lung Cancer Screening Eligibility in United States Veterans.

Am J Prev Med

January 2025

Veterans Health Administration-Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC) and the VETWISE-LHS Center of Innovation, Nashville, TN; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Center for Clinical Quality and Implementation Research, Vanderbilt University Medical Center, Nashville, TN; Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN.

Introduction: Lung cancer screening is underutilized, especially in rural areas where lung cancer mortality is high. Approximately 11.2% of the United States (US) population over age 50 meet the United States Preventive Services Task Force (USPSTF) 2021 lung cancer screening eligibility criteria; the proportion of eligible Veterans is unknown.

View Article and Find Full Text PDF

Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!